Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

N/A
2(66.7%)
Phase 2
1(33.3%)
3Total
N/A(2)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06500936Not ApplicableCompleted

Evaluation of an mHealth Intervention to Promote Participation in Breast Cancer Screening in Argentina

Role: collaborator

NCT04906330Recruiting

Oncoliq: Test for Early Breast Cancer Detection.

Role: collaborator

NCT02095561Not ApplicableCompleted

Evaluation of Human Papilloma Virus (HPV) Self-testing to Increase Screening Uptake

Role: lead

NCT01729663Phase 2Unknown

Phase II/III Clinical Study CSF470 Plus BCG Plus GM-CSF vs IFN Alpha 2b in Stage IIB, IIC and III Melanoma Patients

Role: collaborator

All 4 trials loaded